Business Description
Summit Therapeutics PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BN40HZ01
Description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.98 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 41.3 | |||||
| 3-Year FCF Growth Rate | 43.8 | |||||
| 3-Year Book Growth Rate | -51.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 29.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.31 | |||||
| Quick Ratio | 8.31 | |||||
| Cash Ratio | 8.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -104.1 | |||||
| Shareholder Yield % | 0.88 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -115.11 | |||||
| ROA % | -68.15 | |||||
| ROIC % | -268.04 | |||||
| ROC (Joel Greenblatt) % | -2347.31 | |||||
| ROCE % | -85.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 31.13 | |||||
| Price-to-Tangible-Book | 20 | |||||
| EV-to-EBIT | -71.96 | |||||
| EV-to-EBITDA | -72.73 | |||||
| EV-to-FCF | -116.63 | |||||
| Price-to-Net-Current-Asset-Value | 20 | |||||
| Price-to-Net-Cash | 20 | |||||
| Earnings Yield (Greenblatt) % | -1.39 | |||||
| FCF Yield % | -0.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Summit Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 78.83 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.17 - 0.36 | ||
| Shares Outstanding (Mil) | 336.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Summit Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Summit Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Summit Therapeutics PLC Frequently Asked Questions
What is Summit Therapeutics PLC(FRA:UVF1)'s stock price today?
The current price of FRA:UVF1 is €0.20. The 52 week high of FRA:UVF1 is €0.36 and 52 week low is €0.17.
When is next earnings date of Summit Therapeutics PLC(FRA:UVF1)?
The next earnings date of Summit Therapeutics PLC(FRA:UVF1) is 2025-02-20 Est..
Does Summit Therapeutics PLC(FRA:UVF1) pay dividends? If so, how much?
Summit Therapeutics PLC(FRA:UVF1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers